Work

FRI0342 Does understanding sle matter to disease activity in sle patients?

Year: 2018

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2018-eular.5737

Authors: A.S. Meara, P. Hackenberger, J. Yedimenko, C. Rodman, S.P. Ardoin, E. peters

Institution: The Ohio State University

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Roche, Celgene, Union Chimique Belge, National Institutes of Health, Genentech, EMD Serono, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Award: Complement Activation Signatures in Systemic Lupus Erythematosus: Castle Study

OpenAlex ID: W2808572587

Cites:

Cited by:

Related to: 10